Tuesday, March 21, 2017 3:51:49 PM
PPHM might consider issuing an occasional Letter to Shareholders, along the lines this company did earlier this year, highlighting developments:
"BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, announced that the company mailed a letter to its shareholders updating them on recent developments, market trends, and new business opportunities.
Key Highlights in 2016:
-- BioSig has been featured in three peer-reviewed presentations and publications regarding its collaboration with Mayo Clinic.
-- The most recent MD&D report shows the global Electrophysiology (EP) market revenues will grow nearly 10% annually, from currently $4 billion to approximately $6 billion by 2020.
-- The accompanying procedure growth close to 10% annually, from 865,000 patients in 2015 to 1,350,000 in 2020.
-- The accompanying procedure growth close to 10% annually, from 865,000 patients in 2015 to 1,350,000 in 2020.
-- Management intends to transition to a national exchange this year, and believes that the "uplisting" will provide access to a wider range of investors and analysts.
-- BioSig's article entitled "Novel Electrophysiology Signal Recording System Enables Specific Visualization of the Purkinje Network and Other High-Frequency Signals" was published in the Journal of the American College of Cardiology (JACC): Clinical Electrophysiology.
-- BioSig conducted several studies with its PURE EP System in a ventricular scar model at Mount Sinai Hospital in New York, NY with Dr. Vivek Reddy and his team, which will continue to expand clinical research activities.
-- PURE EP has since entered its seventh Pre-Clinical Trial to further research capabilities of the system.
-- Management engaged Minnetronix, an award winning medical technology and innovation firm, to complete design and development of the first version of the PURE EP System.
-- The Company is currently working with regulatory agencies, both domestically and abroad in order to secure clearance to market and sell the PURE EP System.
-- Successful completion of these submissions would serve as a vital step in achieving commercialization.
-- Successful completion of these submissions would serve as a vital step in achieving commercialization.[more]
Coincidence that BSGM is also + today, announcing a new collaboration with MAYO.
"BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, announced that the company mailed a letter to its shareholders updating them on recent developments, market trends, and new business opportunities.
Key Highlights in 2016:
-- BioSig has been featured in three peer-reviewed presentations and publications regarding its collaboration with Mayo Clinic.
-- The most recent MD&D report shows the global Electrophysiology (EP) market revenues will grow nearly 10% annually, from currently $4 billion to approximately $6 billion by 2020.
-- The accompanying procedure growth close to 10% annually, from 865,000 patients in 2015 to 1,350,000 in 2020.
-- The accompanying procedure growth close to 10% annually, from 865,000 patients in 2015 to 1,350,000 in 2020.
-- Management intends to transition to a national exchange this year, and believes that the "uplisting" will provide access to a wider range of investors and analysts.
-- BioSig's article entitled "Novel Electrophysiology Signal Recording System Enables Specific Visualization of the Purkinje Network and Other High-Frequency Signals" was published in the Journal of the American College of Cardiology (JACC): Clinical Electrophysiology.
-- BioSig conducted several studies with its PURE EP System in a ventricular scar model at Mount Sinai Hospital in New York, NY with Dr. Vivek Reddy and his team, which will continue to expand clinical research activities.
-- PURE EP has since entered its seventh Pre-Clinical Trial to further research capabilities of the system.
-- Management engaged Minnetronix, an award winning medical technology and innovation firm, to complete design and development of the first version of the PURE EP System.
-- The Company is currently working with regulatory agencies, both domestically and abroad in order to secure clearance to market and sell the PURE EP System.
-- Successful completion of these submissions would serve as a vital step in achieving commercialization.
-- Successful completion of these submissions would serve as a vital step in achieving commercialization.[more]
Coincidence that BSGM is also + today, announcing a new collaboration with MAYO.
